Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation

Transplantation

Volumn 83, Issue 11, 2007, Pages 1429-1434

  Pascual, Julio ^a   Mezrich, Joshua D ^a   Djamali, Arjang ^a   Leverson, Glen ^a   Chin, L Thomas ^a   Torrealba, José ^a   Bloom, Debra ^a   Voss, Barbara ^a   Becker, Bryan N ^a   Knechtle, Stuart J ^a   Sollinger, Hans W ^a   Pirsch, John D ^a   Samaniego, Milagros D ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Section of Nephrology   (United States)

Author keywords

Alemtuzumab; Recurrent glomerulonephritis; Thymoglobulin

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECEPTOR BLOCKING AGENT; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DONOR SELECTION; DRUG DOSE REDUCTION; FEMALE; GLOMERULOPATHY; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; LIVING DONORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 34250627560     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000264554.39645.74     Document Type: Article

References (25)

1. Waldmann H, Hale G. CAMPATH: From concept to the clinic. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1707.
2. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005; 5: 1347.
3. Knechtle SJ, Pirsch JD, Fechner J, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot -study. Am J Transplant 2003; 3: 722.
4. Knechtle S, Fernandez LA, Pirsch JD, et al. Campath-1h in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754.
5. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111.
6. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 1602.
7. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibodymediated T-cell depletion. Am J Transplant 2005; 5: 465.
8. Otton SH, Turner DL, Frewin R, Davies SV, Johnson SA. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 261.
9. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (mabcampath) for refractory CLL despite early discontinuation of therapy. Hematologia 2004; 9: 409.
10. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006; 6: 1084.
11. Coles AJ, Cox A, Le Page E. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98.
12. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used? Blood 2007; 109: 2643.
13. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103.
14. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6: 2535.
15. Matas AJ. Recurrent disease after kidney transplantation-It is time to unite to address this problem. Am J Transplant 2006; 6: 2527.
16. Cox AL, Thompson SAJ, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35: 3332.
17. Turgeon N, Samaniego M, Pirsch J et al. Late C4d+- acute rejection: Clinical presentation and response to therapy [Abstract]. Am J Transplant 2005; 5(Suppl 11): 160
18. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613.
19. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006; 82: 1387.
20. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+-CD25+-Foxp3-+ regulatory T cells. J Am Soc Nephrol 2006; 17: 2844.
21. Hubsch H, Montane B, Abitbol C, et al. Recurrent focal glomerulosclerosis in pediatric renal allografts: The Miami experience. Pediatr Nephrol 2005; 20: 210.
22. Sheth RD, Kale AS, Goldstein SL, Brewer ED. Rapid recurrence of posttransplant FSGS after daclizumab induction. Pediatr Nephrol 2001; 16: C190.
23. Pardon A, Audard V, Caillard S, et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 2006; 21: 1053.
24. Bunnapradist S, Chung P, Peng A, et al. Outcomes of renal transplantation for recipients with lupus nephritis: Analysis of the organ procurement and transplantation network database. Transplantation 2006; 82: 612.
25. Kirk AD. Induction immunosuppression. Transplantation 2006; 82: 593.